Concepcion Peiro

List of Publications by Year
in descending order

82 papers	4,147 citations	126708 33 h-index	114278 63 g-index
83 all docs	83 docs citations	83 times ranked	6886 citing authors

#	Article	IF	Citations
1	Pharmacological Blockade of NLRP3 Inflammasome/IL-1Î²-Positive Loop Mitigates Endothelial Cell Senescence and Dysfunction. , 2022, 13, 284.		19
2	NLRP3 Inflammasome in Vascular Disease: A Recurrent Villain to Combat Pharmacologically. Antioxidants, 2022, 11, 269.	2.2	6
3	DPP4 Promotes Human Endothelial Cell Senescence and Dysfunction via the PAR2â€"COX-2â€"TP Axis and NLRP3 Inflammasome Activation. Hypertension, 2022, 79, 1361-1373.	1.3	14
4	Resolvin E1 attenuates doxorubicin-induced endothelial senescence by modulating NLRP3 inflammasome activation. Biochemical Pharmacology, 2022, 201, 115078.	2.0	6
5	Obesity, A Condition That Mimics Premature Aging. , 2021, , 501-521.		2
6	Resolvin D1 and E1 promote resolution of inflammation in rat cardiac fibroblast in vitro. Molecular Biology Reports, 2021, 48, 57-66.	1.0	16
7	Resolvin D1 reduces expression and secretion of cytokines and monocyte adhesion triggered by Angiotensin II, in rat cardiac fibroblasts. Biomedicine and Pharmacotherapy, 2021, 141, 111947.	2.5	3
8	Resolvin-D1 attenuation of angiotensin II-induced cardiac inflammation in mice is associated with prevention of cardiac remodeling and hypertension. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166241.	1.8	15
9	Cardiovascular Damage in COVID-19: Therapeutic Approaches Targeting the Renin-Angiotensin-Aldosterone System. International Journal of Molecular Sciences, 2020, 21, 6471.	1.8	21
10	DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?. Frontiers in Pharmacology, 2020, 11, 1161.	1.6	80
11	Visfatin/eNampt induces endothelial dysfunction in vivo: a role for Toll-Like Receptor 4 and NLRP3 inflammasome. Scientific Reports, 2020, 10, 5386.	1.6	69
12	Polyphenols Attenuate Highly-Glycosylated Haemoglobin-Induced Damage in Human Peritoneal Mesothelial Cells. Antioxidants, 2020, 9, 572.	2.2	3
13	Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARS-CoV-2 Infection?. Circulation, 2020, 141, 1665-1666.	1.6	57
14	The angiotensinâ€(1â€7)/Mas receptor axis protects from endothelial cell senescence via klotho and Nrf2 activation. Aging Cell, 2019, 18, e12913.	3.0	80
15	Role of glutathione biosynthesis in endothelial dysfunction and fibrosis. Redox Biology, 2018, 14, 88-99.	3.9	63
16	Heparan sulfate potentiates leukocyte adhesion on cardiac fibroblast by enhancing Vcam-1 and Icam-1 expression. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 831-842.	1.8	29
17	Genome-Wide Inhibition of Pro-atherogenic Gene Expression by Multi-STAT Targeting Compounds as a Novel Treatment Strategy of CVDs. Frontiers in Immunology, 2018, 9, 2141.	2.2	7
18	The adipokine visfatin produces murine endothelial dysfunction in vivo and ex vivo: opportunities for pharmacological interventions. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR10-3.	0.0	0

#	Article	IF	Citations
19	High concentration of branched-chain amino acids promotes oxidative stress, inflammation and migration of human peripheral blood mononuclear cells via mTORC1 activation. Free Radical Biology and Medicine, 2017, 104, 165-177.	1.3	241
20	Mas receptor is involved in the estrogen-receptor induced nitric oxide-dependent vasorelaxation. Biochemical Pharmacology, 2017, 129, 67-72.	2.0	34
21	Dual Effects of Resveratrol on Cell Death and Proliferation of Colon Cancer Cells. Nutrition and Cancer, 2017, 69, 1019-1027.	0.9	38
22	IL-1Î² Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus. Frontiers in Pharmacology, 2017, 8, 363.	1.6	92
23	The Angiotensin-(1-7)/Mas Axis Counteracts Angiotensin II-Dependent and -Independent Pro-inflammatory Signaling in Human Vascular Smooth Muscle Cells. Frontiers in Pharmacology, 2016, 7, 482.	1.6	32
24	Soluble dipeptidyl peptidase-4 induces microvascular endothelial dysfunction through proteinase-activated receptor-2 and thromboxane A2 release. Journal of Hypertension, 2016, 34, 869-876.	0.3	40
25	Inflammation, glucose, and vascular cell damage: the role of the pentose phosphate pathway. Cardiovascular Diabetology, 2016, 15, 82.	2.7	84
26	Combined Sub-Optimal Doses of Rosuvastatin and Bexarotene Impair Angiotensin II-Induced Arterial Mononuclear Cell Adhesion Through Inhibition of Nox5 Signaling Pathways and Increased RXR/PPARÎ± and RXR/PPARÎ³ Interactions. Antioxidants and Redox Signaling, 2015, 22, 901-920.	2.5	22
27	The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats. Cardiovascular Diabetology, 2014, 13, 158.	2.7	93
28	Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1613-1621.	1.8	116
29	Visfatin/Nampt induces telomere damage and senescence in human endothelial cells. International Journal of Cardiology, 2014, 175, 573-575.	0.8	14
30	High-cholesterol diet enriched with onion affects endothelium-dependent relaxation and NADPH oxidase activity in mesenteric microvessels from Wistar rats. Nutrition and Metabolism, 2014, 11, 57.	1.3	22
31	Endothelial C-type natriuretic peptide maintains vascular homeostasis. Journal of Clinical Investigation, 2014, 124, 4039-4051.	3.9	125
32	Visfatin/Nampt: An Adipokine with Cardiovascular Impact. Mediators of Inflammation, 2013, 2013, 1-15.	1.4	147
33	Complete blockade of the vasorelaxant effects of angiotensinâ€(1â€"7) and bradykinin in murine microvessels by antagonists of the receptor Mas. Journal of Physiology, 2013, 591, 2275-2285.	1.3	28
34	Visfatin as a Novel Mediator Released by Inflamed Human Endothelial Cells. PLoS ONE, 2013, 8, e78283.	1.1	46
35	Mechanisms Involved in the Aging-Induced Vascular Dysfunction. Frontiers in Physiology, 2012, 3, 132.	1.3	163
36	Characterization of endothelium-dependent relaxations in the mesenteric vasculature: a comparative study with potential pathophysiological relevance. Journal of Pediatric Surgery, 2012, 47, 2044-2049.	0.8	2

#	Article	IF	Citations
37	DisfunciÃ³n endotelial asociada al envejecimiento vascular humano. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2011, 23, 135-139.	0.4	0
38	Phorbol Dibutyrate Induces Contractions in Bovine Cerebral Arteries by an Extracellular Calcium-independent Mechanism. Journal of Pharmacy and Pharmacology, 2011, 45, 274-279.	1.2	3
39	Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate. European Journal of Pharmacology, 2011, 667, 153-159.	1.7	56
40	Pathways Responsible for Apoptosis Resulting from Amadori-Induced Oxidative and Nitrosative Stress in Human Mesothelial Cells. American Journal of Nephrology, 2011, 34, 104-114.	1.4	6
41	Visfatin Impairs Endothelium-Dependent Relaxation in Rat and Human Mesenteric Microvessels through Nicotinamide Phosphoribosyltransferase Activity. PLoS ONE, 2011, 6, e27299.	1.1	56
42	Visfatin/PBEF/Nampt: A New Cardiovascular Target?. Frontiers in Pharmacology, 2010, 1, 135.	1.6	28
43	Inflammation Determines the Pro-Adhesive Properties of High Extracellular D-Glucose in Human Endothelial Cells In Vitro and Rat Microvessels In Vivo. PLoS ONE, 2010, 5, e10091.	1.1	58
44	The Novel Antioxidant, AC3056 (2,6-di-t-butyl-4-((Dimethyl-4-Methoxyphenylsilyl)Methyloxy)Phenol), Reverses Erectile Dysfunction in Diabetic Rats and Improves NO-mediated Responses in Penile Tissue from Diabetic Men. Journal of Sexual Medicine, 2009, 6, 373-387.	0.3	32
45	Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia, 2009, 52, 2455-2463.	2.9	128
46	Endothelial dysfunction in aged humans is related with oxidative stress and vascular inflammation. Aging Cell, 2009, 8, 226-238.	3.0	188
47	Characterization of the Human Î±1Î²1 Soluble Guanylyl Cyclase Promoter. Journal of Biological Chemistry, 2008, 283, 20027-20036.	1.6	23
48	The deleterious effect of high concentrations of D-glucose requires pro-inflammatory preconditioning. Journal of Hypertension, 2008, 26, 478-485.	0.3	26
49	Endothelial dysfunction through genetic deletion or inhibition of the G protein-coupled receptor Mas: a new target to improve endothelial function. Journal of Hypertension, 2007, 25, 2421-2425.	0.3	74
50	Xanthine oxidase-derived extracellular superoxide anions stimulate activator protein 1 activity and hypertrophy in human vascular smooth muscle via c-Jun N-terminal kinase and p38 mitogen-activated protein kinases. Journal of Hypertension, 2007, 25, 609-618.	0.3	25
51	Proâ€inflammatory effects of early nonâ€enzymatic glycated proteins in human mesothelial cells vary with cell donor's age. British Journal of Pharmacology, 2006, 149, 979-987.	2.7	8
52	Changes in the human peritoneal mesothelial cells during aging. Kidney International, 2006, 69, 313-322.	2.6	26
53	Evidence for Sodium Azide as an Artifact Mediating the Modulation of Inducible Nitric Oxide Synthase by C-Reactive Protein. Journal of Cardiovascular Pharmacology, 2005, 45, 193-196.	0.8	36
54	Amadori adducts activate nuclear factor-Îº B-related proinflammatory genes in cultured human peritoneal mesothelial cells. British Journal of Pharmacology, 2005, 146, 268-279.	2.7	38

#	Article	IF	Citations
55	A Phase I Clinical Trial of the Treatment of Crohn's Fistula by Adipose Mesenchymal Stem Cell Transplantation. Diseases of the Colon and Rectum, 2005, 48, 1416-1423.	0.7	728
56	Early and intermediate Amadori glycosylation adducts, oxidative stress, and endothelial dysfunction in the streptozotocin-induced diabetic rats vasculature. Diabetologia, 2003, 46, 556-566.	2.9	66
57	Glycosylated human oxyhaemoglobin activates nuclear factor-Îº B and activator protein-1 in cultured human aortic smooth muscle. British Journal of Pharmacology, 2003, 140, 681-690.	2.7	24
58	Effect of glycaemic control on the vascular nitric oxide system in patients with type 1 diabetes. Journal of Hypertension, 2003, 21, 1137-1143.	0.3	27
59	High glucose induces cell death of cultured human aortic smooth muscle cells through the formation of hydrogen peroxide. British Journal of Pharmacology, 2001, 133, 967-974.	2.7	73
60	Differential effects of serotonin reuptake inhibitors on erectile responses, NO-production, and neuronal NO synthase expression in rat corpus cavernosum tissue. British Journal of Pharmacology, 2001, 134, 1190-1194.	2.7	75
61	Prevention of endothelial dysfunction in streptozotocin-induced diabetic rats by gliclazide treatment. Journal of Diabetes and Its Complications, 2000, 14, 224-233.	1.2	31
62	Correction of glycosylated oxyhemoglobin-induced impairment of endothelium-dependent vasodilatation by gliclazide. Journal of Diabetes and Its Complications, 2000, 14, 207-214.	1.2	9
63	Highly glycated oxyhaemoglobin impairs nitric oxide relaxations in human mesenteric microvessels. Diabetologia, 2000, 43, 83-90.	2.9	52
64	Enhancement of S-Nitrosylation in Glycosylated Hemoglobin. Biochemical and Biophysical Research Communications, 2000, 271, 217-221.	1.0	30
65	Treatment with Acarbose May Improve Endothelial Dysfunction in Streptozotocin-Induced Diabetic Rats. Journal of Cardiovascular Pharmacology, 2000, 36, 255-262.	0.8	30
66	Thapsigargin Induces Apoptosis in Cultured Human Aortic Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 2000, 36, 676-680.	0.8	7
67	Pharmacological interference of vascular smooth muscle cell hypertrophy induced by glycosylated human oxyhaemoglobin. European Journal of Pharmacology, 1999, 386, 317-321.	1.7	1
68	Impairment of endothelial relaxations by glycosylated human oxyhemoglobin depends on the oxidative state of the heme group. General Pharmacology, 1999, 32, 475-481.	0.7	7
69	Endothelial dysfunction and metabolic control in streptozotocin-induced diabetic rats. British Journal of Pharmacology, 1998, 123, 1495-1502.	2.7	63
70	Vascular smooth muscle cell hypertrophy induced by glycosylated human oxyhaemoglobin. British Journal of Pharmacology, 1998, 125, 637-644.	2.7	14
71	Impairment of nitric oxide-mediated relaxations in anaesthetized autoperfused streptozotocin-induced diabetic rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 358, 529-537.	1.4	36
72	Endogenous Angiotensin II and Cell Hypertrophy in Vascular Smooth Muscle Cultures from Hypertensive Ren-2 Transgenic Rats. Cellular Physiology and Biochemistry, 1998, 8, 106-116.	1.1	7

#	Article	IF	Citations
73	Nifedipine, losartan and captopril effects on hyperplasia of vascular smooth muscle from Ren-2 transgenic rats. European Journal of Pharmacology, 1997, 324, 257-265.	1.7	7
74	Angiotensin II Mediates Cell Hypertrophy in Vascular Smooth Muscle Cultures from Hypertensive Ren-2 Transgenic Rats by an Amiloride- and Furosemide-Sensitive Mechanism. Biochemical and Biophysical Research Communications, 1997, 240, 367-371.	1.0	7
75	Effects of captopril, losartan, and nifedipine on cell hypertrophy of cultured vascular smooth muscle from hypertensive Ren-2 transgenic rats. British Journal of Pharmacology, 1997, 121, 1438-1444.	2.7	10
76	Effects of Indomethacin and Iloprost on Contraction of the Afferent Arterioles by Endothelin-1 in Juxtamedullary Nephron Preparations from Normotensive Wistar-Kyoto and Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 1996, 28, 809-816.	0.8	6
77	Impairment of Endothelium-Dependent Relaxation by Increasing Percentages of Glycosylated Human Hemoglobin. Hypertension, 1996, 28, 583-592.	1.3	65
78	Influence of Endothelium on Cultured Vascular Smooth Muscle Cell Proliferation. Hypertension, 1995, 25, 748-751.	1.3	57
79	Endothelial Stimulation of Sodium Pump in Cultured Vascular Smooth Muscle. Hypertension, 1995, 26, 177-185.	1.3	10
80	Functional vascular renin-angiotensin system in hypertensive transgenic rats for the mouse renin gene Ren-2. General Pharmacology, 1994, 25, 1163-1170.	0.7	25
81	Vascular Smooth Muscle Proliferation in Hypertensive Transgenic Rats. Journal of Cardiovascular Pharmacology, 1992, 20, S128-S131.	0.8	17
82	Comparison of the vasoconstrictor responses induced by endothelin and phorbol 12,13-dibutyrate in bovine cerebral arteries. Brain Research, 1992, 599, 186-196.	1.1	20